# Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above

> **NCT01879553** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 126 (actual)

## Conditions studied

- Human Influenza

## Interventions

- **BIOLOGICAL:** TIV

## Key facts

- **NCT ID:** NCT01879553
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2014-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01879553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01879553, "Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT01879553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*